Chang-Rabley E, van Zelm M, Ricotta E, Edwards E
Vaccines (Basel). 2024; 12(6).
PMID: 38932404
PMC: 11209597.
DOI: 10.3390/vaccines12060675.
Amani B, Amani B
Immun Inflamm Dis. 2024; 12(4):e1262.
PMID: 38652021
PMC: 11037253.
DOI: 10.1002/iid3.1262.
Iketani S, Ho D
Cell Chem Biol. 2024; 31(4):632-657.
PMID: 38640902
PMC: 11084874.
DOI: 10.1016/j.chembiol.2024.03.008.
Lo C, Lo C, Komorowski A, Leung V, Matic N, McKenna S
BMC Res Notes. 2024; 17(1):37.
PMID: 38267971
PMC: 10809552.
DOI: 10.1186/s13104-024-06695-x.
Young-Xu Y, Korves C, Zwain G, Satram S, Drysdale M, Reyes C
Open Forum Infect Dis. 2023; 10(12):ofad605.
PMID: 38152625
PMC: 10751450.
DOI: 10.1093/ofid/ofad605.
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review.
Drysdale M, Gibbons D, Singh M, Rolland C, Lavoie L, Skingsley A
Infection. 2023; 52(1):1-17.
PMID: 37776474
PMC: 10811031.
DOI: 10.1007/s15010-023-02098-5.
Neutralization, effector function and immune imprinting of Omicron variants.
Addetia A, Piccoli L, Case J, Park Y, Beltramello M, Guarino B
Nature. 2023; 621(7979):592-601.
PMID: 37648855
PMC: 10511321.
DOI: 10.1038/s41586-023-06487-6.
Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial.
Shapiro A, Sarkis E, Acloque J, Free A, Gonzalez-Rojas Y, Hussain R
Open Forum Infect Dis. 2023; 10(8):ofad354.
PMID: 37577112
PMC: 10414803.
DOI: 10.1093/ofid/ofad354.
Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial.
Moya J, Temech M, Parra S, Juarez E, Hernandez-Loy R, Gutierrez J
Open Forum Infect Dis. 2023; 10(7):ofad344.
PMID: 37520411
PMC: 10372714.
DOI: 10.1093/ofid/ofad344.
Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2.
Candel F, Barreiro P, Salavert M, Cabello A, Fernandez-Ruiz M, Perez-Segura P
Viruses. 2023; 15(7).
PMID: 37515137
PMC: 10383267.
DOI: 10.3390/v15071449.
Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections.
Miyashita N, Nakamori Y, Ogata M, Fukuda N, Yamura A, Ishiura Y
Viruses. 2023; 15(6).
PMID: 37376600
PMC: 10302949.
DOI: 10.3390/v15061300.
Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated with monoclonal antibodies.
Candel F, Salavert M, Lorite Mingot D, Manzano Crespo M, Perez Portero P, Cuervo Pinto R
Rev Esp Quimioter. 2023; 36(4):380-391.
PMID: 37089055
PMC: 10336315.
DOI: 10.37201/req/023.2023.
Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.
Planas D, Bruel T, Staropoli I, Guivel-Benhassine F, Porrot F, Maes P
Nat Commun. 2023; 14(1):824.
PMID: 36788246
PMC: 9926440.
DOI: 10.1038/s41467-023-36561-6.
A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19).
Widyasari K, Kim J
Antibodies (Basel). 2023; 12(1).
PMID: 36648889
PMC: 9887598.
DOI: 10.3390/antib12010005.
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA.
Cheng M, Reyes C, Satram S, Birch H, Gibbons D, Drysdale M
Infect Dis Ther. 2023; 12(2):607-621.
PMID: 36629998
PMC: 9832411.
DOI: 10.1007/s40121-022-00755-0.
Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir.
Martin-Blondel G, Marcelin A, Soulie C, Kaisaridi S, Lusivika-Nzinga C, Zafilaza K
Clin Microbiol Infect. 2022; 29(4):543.e5-543.e9.
PMID: 36586513
PMC: 9794519.
DOI: 10.1016/j.cmi.2022.12.016.
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies.
Bruel T, Stefic K, Nguyen Y, Toniutti D, Staropoli I, Porrot F
Cell Rep Med. 2022; 3(12):100850.
PMID: 36450283
PMC: 9706550.
DOI: 10.1016/j.xcrm.2022.100850.
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies.
Planas D, Bruel T, Staropoli I, Guivel-Benhassine F, Porrot F, Maes P
bioRxiv. 2022; .
PMID: 36415455
PMC: 9681044.
DOI: 10.1101/2022.11.17.516888.
[Update of the recommendations on the management of the SARS-CoV-2 coronavirus pandemic (COVID-19) in kidney transplant patients.].
Lopez V, Mazuecos A, Villanego F, Lopez-Oliva M, Alonso A, Beneyto I
Nefrologia. 2022; .
PMID: 36405492
PMC: 9664833.
DOI: 10.1016/j.nefro.2022.11.001.
COVID-19 in donation and transplant.
Candel F, Pardo Rey C, Torres-Gonzalez J, Fernandez-Vega P, Fragiel M, Oteo D
Rev Esp Quimioter. 2022; 35 Suppl 3:54-62.
PMID: 36285860
PMC: 9717455.
DOI: 10.37201/req/s03.13.2022.
